TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training

Regulations Post-Brexit Impact on Pharma & LifeSciences

Brexit taskforce team

Graham Donaldson
Graham Donaldson

Director, Regulatory Affairs

Linkedin
Jon Jeffery
Jon Jeffery

Head UK/IE Region & Managing Director UK

Linkedin
Jane Lyons
Jane Lyons

Country Manager, Ireland

Linkedin
Jürgen Hönig
Jürgen Hönig

Senior Director, Regulatory Business Intelligence

Linkedin

PharmaLex Talks – Home of the Pharmalex Talks podcast

We recently launched a podcast to cover topics pertinent to the pharma industry. In our first podcast episode titled “Post Brexit landscape for the pharmaceutical industry” we talk about the following topics:

✔Adapting regulations Post-Brexit
✔What was the cost to the pharmaceutical industry as a result of Brexit, and the difficulties with the supply of safe and compliant medicines.
✔How have companies been approaching the requirements around the Northern Ireland Protocol.
✔How can pharma companies practically manage FMD requirements from January 2022.
✔What other deadlines should the pharma industry be aware of.

Our first guest is PharmaLex expert Charley Maxwell.

GO TO PHARMALEX TALKS
PharmaLex Talks

Regulations Post-Brexit Impact on Pharma & LifeSciences

READ OUR Q&A

Related News

Employee Spotlight. Get to know our Team
Employee Spotlight. Get to know our Team
28th July 2021
MD Regulatory transition under Brexit
MD Regulatory transition under Brexit
15th December 2020
Brexit transition period drawing to a close
Brexit transition period drawing to a close
15th September 2020

Related Resources

Thought Leadership

  • In the case of a ‘no deal’ Brexit: the supply of medicines
  • EMA simplifies the process for internal transfer of MAs
  • Brexit Uncertainty - impact on medicines supply

White Papers

  • UK Pharmacovigilance Requirements Following the End of the Brexit Transition Period
  • How will Medical Devices be regulated following the end of the Brexit Transition Period
  • Brexit Considerations for Industry: The current Position

Webinars

  • Post-Brexit 2021 Health and Life Science Sector Impact – Legal and Regulatory Overview
  • Brexit – Preparing for the end of the transition period and beyond
  • Brexit: An update on preparations for MA holders

Related Services

  • Clinical Trial Applications
  • Commercialization Readiness
  • EU QPPV / National QPPV
  • Global Procedure Management
  • MAA / NDA Submissions
  • Market Access
  • Marketing and Labeling Activities
  • MedTech Services

News & Events

  • Resilience of Pharma Supply Chains and the Impact of Covid-19 Pandemic

    Resilience of Pharma Supply Chains and the Impact of Covid-19 Pandemic

    17th May 2021
  • Rules on Ownership of Medicinal Product stock distributed in Great Britain

    Rules on Ownership of Medicinal Product stock distributed in Great Britain

    7th April 2021
  • Brexit transition period drawing to a close

    Brexit transition period drawing to a close

    15th September 2020
  • Utmost priority – avoiding supply chain disruptions

    Utmost priority – avoiding supply chain disruptions

    10th September 2020
  • Taking a pragmatic approach to Brexit

    Taking a pragmatic approach to Brexit

    9th September 2020
  • BREXIT: Medical Device/Combination Products – Key changes

    BREXIT: Medical Device/Combination Products – Key changes

    3rd September 2020
  • BREXIT: Pharmacovigilance – Key changes

    BREXIT: Pharmacovigilance – Key changes

    3rd September 2020
  • BREXIT: Pharmaceutical Products and Import/Export – Key Changes

    BREXIT: Pharmaceutical Products and Import/Export – Key Changes

    3rd September 2020
  • BREXIT: Clinical Trials – Key changes

    BREXIT: Clinical Trials – Key changes

    3rd September 2020
  • Clinical trials in the post Brexit Europe

    Clinical trials in the post Brexit Europe

    24th August 2020
  • Brexit: Guidance on Batch Testing

    Brexit: Guidance on Batch Testing

    9th May 2019
  • Quality Considerations for Manufacturing in Pharma

    Quality Considerations for Manufacturing in Pharma

    30th April 2019
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Our project team were very impressed with the quality of the research and the reports that you sent through. We didn’t need any convincing that your recommendations should be followed. It showed PharmaLex in a very positive light, and the Project Team are keen to work with you again.

    Leading European Specialist Pharma Company
    Head of Medical Writing and Publications
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for